YZi Labs invests in regenerative medicine company Renewal Bio

Foresight News reported that YZi Labs has announced an investment in the regenerative medicine company Renewal Bio, marking YZi Labs' first biotechnology investment since expanding its investment scope in early 2025. Renewal Bio focuses on using its proprietary Stembroid™ platform to generate human cells and tissues with fully matched DNA from patients' own cells, aiming to address the global organ shortage crisis.

Renewal Bio reprograms ordinary skin or blood cells into stem cells by simulating early human developmental environments, generating various functional cells including hematopoietic, liver, heart, and pancreatic cells. The company was co-founded in 2022 by Professor Jacob Hanna of the Weizmann Institute of Science and his two doctoral students, Vladislav Krupalnik and Ohad Gafni. This round of financing will accelerate the preclinical development of Stembroid-derived hematopoietic stem cells for the treatment of leukemia and immune diseases, and support the expansion of laboratory infrastructure.